Spots Global Cancer Trial Database for multiple myeloma
Every month we try and update this database with for multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | NCT00473590 | Multiple Myelom... | Bevacizumab Bortezomib placebo | 18 Years - | Genentech, Inc. | |
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | NCT00434161 | Multiple Myelom... | Palifermin befo... Placebo Palifermin befo... | 18 Years - 70 Years | Swedish Orphan Biovitrum | |
| The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma | NCT05331313 | Multiple Myelom... | DNA sequencing | 18 Years - | Hospices Civils de Lyon | |
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02477215 | Multiple Myelom... | MLN9708 Dexamethasone Bendamustine (m... Bendamustine (M... | 18 Years - | Medical College of Wisconsin | |
| DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | NCT00083681 | Multiple Myelom... | Thalidomide Dexamethasone Cytoxan Etoposide Cisplatin G-CSF | 18 Years - | University of Arkansas | |
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant | NCT01416246 | Multiple Myelom... | Fractionated St... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | NCT00445068 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Quality of Life in Multiple Myeloma Patients Treated With Bortezomib | NCT01021592 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma | NCT01619358 | Multiple Myelom... | 21 Years - | National University Hospital, Singapore | ||
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | NCT00116441 | Multiple Myelom... | Therapeutic Cel... | 18 Years - 70 Years | Cell Genesys | |
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | NCT02204241 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 65 Years - | Stichting European Myeloma Network | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma | NCT02043860 | Multiple Myelom... | Total Marrow Ir... Autologous Tran... Melphalan Filgrastim (G-C... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | NCT04955808 | Breast Carcinom... Colon Carcinoma Invasive Carcin... Kidney Carcinom... Liver Carcinoma Malignant Solid... Multiple Myelom... Prostate Carcin... | Biospecimen Col... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use | NCT02922543 | Multiple Myelom... | 18 Years - | Celgene | ||
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project. | NCT05306587 | Multiple Myelom... | Darzalex | 18 Years - | Odense University Hospital | |
| Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT01348919 | Multiple Myelom... | CEP-18770 Lenalidomide Dexamethasone | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 | NCT04746092 | CLL Multiple Myelom... Lymphoma | 18 Years - 100 Years | Tel-Aviv Sourasky Medical Center | ||
| PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | NCT00319865 | Multiple Myelom... | Velcade Thalidomide Adriamycin Dexamethasone | 0 Years - 75 Years | Korean Multiple Myeloma Working Party | |
| Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma | NCT04671251 | Multiple Myelom... | AEVI-007 | 18 Years - | Avalo Therapeutics, Inc. | |
| Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | NCT03915184 | Multiple Myelom... | zevor-cel | 18 Years - 79 Years | CARsgen Therapeutics Co., Ltd. | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | NCT01658904 | Multiple Myelom... Leukemia, Plasm... | Carfilzomib Melphalan Filgrastim | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma | NCT02157636 | Multiple Myelom... | CPI-0610 | 18 Years - | Constellation Pharmaceuticals | |
| Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | NCT02056756 | Multiple Myelom... | Carfilzomib | 18 Years - | Stichting European Myeloma Network | |
| Home Treatment With Carfilzomib in Patients With Multiple Myeloma | NCT05620238 | Multiple Myelom... | Carfilzomib | 18 Years - | Odense University Hospital | |
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | NCT03850704 | Multiple Myelom... | Selinexor | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | NCT03486067 | Multiple Myelom... | CC-93269 | 18 Years - | Celgene | |
| Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | NCT02909036 | Multiple Myelom... Amyloidosis | Melphalan Pegfilgrastim Autologous Hema... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | NCT05802992 | Multiple Myelom... | Colchicine Lenalidomide | 18 Years - 80 Years | Affiliated Hospital of Nantong University | |
| STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | NCT02586038 | Multiple Myelom... | MLN9708 Dexamethasone Cyclophosphamid... Thalidomide | 65 Years - | University of Turin, Italy | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma | NCT02919670 | Multiple Myelom... Non-Hodgkin's L... | Enterade Placebo Standard Suppor... | 18 Years - | Dana-Farber Cancer Institute | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | NCT03670173 | Multiple Myelom... | Osalmid | 18 Years - | Shanghai 10th People's Hospital | |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma | NCT04452994 | Multiple Myelom... | JNJ-68284528 | - | Janssen Research & Development, LLC | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | NCT01054144 | Multiple Myelom... | Lenalidomide Prednisone Dexamethasone | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients | NCT04770402 | Chemotherapy-in... | Acupuncture Standard of Car... | 18 Years - | Wake Forest University Health Sciences | |
| A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice | NCT04659798 | Multiple Myelom... Immunoglobulin ... | 18 Years - | Takeda | ||
| Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | NCT06160167 | Multiple Myelom... | IMiD treatment No IMiD treatme... Systemic therap... | 18 Years - | Bristol-Myers Squibb | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI | NCT04493411 | Multiple Myelom... | WBMRI Positron Emissi... | 18 Years - | University of Texas Southwestern Medical Center | |
| A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure | NCT01241396 | Multiple Myelom... | Any MMY treatme... | 18 Years - 99 Years | Janssen Pharmaceutica N.V., Belgium | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | NCT03104842 | Multiple Myelom... | Isatuximab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| ctDNA Methylation Sequencing for Myeloma | NCT05578625 | Multiple Myelom... | plasma circulat... | 18 Years - 75 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | NCT06066346 | Multiple Myelom... | Talquetamab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291 | Hematologic Mal... | Romiplostim | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation | NCT06328699 | Lymphoma Multiple Myelom... | Spiritual Thera... Best Practice | 18 Years - | Emory University | |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) | NCT02955810 | Multiple Myelom... | Daratumumab Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 70 Years | National University of Ireland, Galway, Ireland | |
| Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | NCT01159574 | Multiple Myelom... | dexamethasone clarithromycin Pomalidomide | 18 Years - | Weill Medical College of Cornell University | |
| Study of XL999 in Patients With Multiple Myeloma | NCT00304590 | Multiple Myelom... | XL999 | 18 Years - | Symphony Evolution, Inc. | |
| Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | NCT05336383 | Multiple Myelom... Plasma Cell Neo... Malignant Plasm... | Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | NCT05172596 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy | NCT00205764 | Multiple Myelom... | Melphalan | 19 Years - 70 Years | Austrian Forum Against Cancer | |
| Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | NCT04714827 | Multiple Myelom... | KQ-2003 CAR-T c... | 18 Years - | Shanxi Province Cancer Hospital | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | NCT00807599 | Multiple Myelom... | Stem cell trans... lenalidomide an... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects | NCT01980589 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 18 Years - | Amgen | |
| Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | NCT00024466 | Multiple Myelom... | GVAX Autologous tran... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | NCT05289492 | Multiple Myelom... | EOS884448 Iberdomide Dexamethasone | 18 Years - | iTeos Therapeutics | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | NCT01943851 | Neoplasms | GSK525762 | 18 Years - | GlaxoSmithKline | |
| A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | NCT05181501 | Multiple Myelom... | Fully human BCM... | 18 Years - 70 Years | Nanjing IASO Biotechnology Co., Ltd. | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | NCT00006184 | Multiple Myelom... | Myeloma Immunog... Bortezomib Cyclophosphamid... Cyclosporine Doxorubicin hyd... Etoposide Fludarabine pho... Prednisone Vincristine Sul... Methotrexate GMCSF (granuloc... GCSF (granulocy... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | NCT06160167 | Multiple Myelom... | IMiD treatment No IMiD treatme... Systemic therap... | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
